Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Remimazolam versus dexmedetomidine for sedation in severe neurologic disease
ChiCTR2100045313Phase 4Recruiting
- Sponsor
- Zhangjiajie People's Hospital
- Start
- Apr 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of remimazolam and dexmedetomidine in neurological diseases (2 arms), sponsored by Zhangjiajie People's Hospital. Primary endpoints: Time required to reach sedation depth, Single medication to achieve target sedation rate and 1 more. Started Apr 2021; status: recruiting.
02
Drugs
remimazolamdexmedetomidine
03
Conditions
neurological diseases
Beyond the preview
Go deeper on ChiCTR2100045313.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2100045313.